GLPwatch
Papers (9189)
Page 114 of 154, ranked by citation count.
- The combination of a glucagon-like peptide-1 and amylin receptor agonists reduces alcohol consumption in both male and female rats.
- Liraglutide attenuates high glucose-induced endothelial cell senescence and dysfunction via SIRT1-mediated deacetylation of p53/p65.
- Contractile effects of retatrutide in isolated mouse atrial preparations.
- Liraglutide alleviates vascular injury in diabetic rabbits with lower limb vascular stenosis through regulation of RCAN1.
- The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus.
- The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetes.
- Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
- Design of a novel long-acting dual GLP-1/GIP receptor agonist.
- Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.
- Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.
- Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
- Money being paid for prescribing Wegovy in pilot studies is "over the top," say critics.
- Liraglutide in Children and Teens with Type 2 Diabetes. Reply.
- The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous?
- Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain-Reply.
- Liraglutide attenuates doxorubicin-induced cardiomyocyte ferroptosis via DHHC7-mediated STAT3 palmitoylation.
- Place in therapy for liraglutide and saxagliptin for type 2 diabetes.
- Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.
- Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.
- Treatment of Bile Acid Diarrhea With Glucagon-Like Peptide 1 Receptor Agonists: A Promising Yet Understudied Approach.
- Microvascular and macrovascular effects of liraglutide.
- A phase I study comparing the pharmacokinetics of the biosimilar (RD12014) with liraglutide (Victoza) in healthy Chinese male subjects.
- Combined Insulin and GLP-1 Receptor Agonists: Simplifying Treatment or Adding Obstacles?
- The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?
- Glycemic control and the heart: it matters how you get there.
- [Anti-obesity drugs : from previous disappointments to new hopes].
- Exploring omics signature in the cardiovascular response to semaglutide: Mechanistic insights and clinical implications.
- Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.
- Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study.
- Epicardial adipose tissue and residual cardiovascular risk: a comprehensive case analysis and therapeutic insights with Liraglutide.
- Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.
- What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus.
- [LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE TREATMENT OF OBESITY].
- In overweight or obese adults without diabetes, semaglutide increased weight loss and GI disorders.
- Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol.
- Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.
- Treatment effect of semaglutide 2.4 mg on health-related quality of life from STEP 1 SF-6D derived from SF-36 with Australian weights.
- Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications.
- Liraglutide Treatment Reverses Unconventional Cellular Defects in Induced Pluripotent Stem Cell-Derived β-Cells Harboring a Partially Functional WFS1 Variant.
- Efficacy and Safety of Basal Insulin/GLP-1 Receptor Agonist Used in Combination for Type 2 Diabetes Management.
- Utilising Health Technology Assessment to Develop Managed Access Protocols to Facilitate Drug Reimbursement in Ireland.
- Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain.
- The role of nanosystems in the delivery of glucose-lowering drugs for the preemption and treatment of diabetes-associated atherosclerosis.
- A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
- Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus.
- Basal insulin or longacting GLP-1 receptor agonists-making the right choice.
- Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with polycystic ovary syndrome: a retrospective study.
- [The incretin effect and type 2 diabetes].
- Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.
- Liraglutide limits the immunogenic cell death-mediated ROS propagation and PI3K/AKT inactivation after doxorubicin-induced gonadotoxicity in rats: Involvement of the canonical Hedgehog trajectory.
- Effectiveness of liraglutide in the treatment of adolescent obesity.
- Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes.
- GLP-1 Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management.
- Comparing the Efficacy of Liraglutide and Semaglutide on Weight Loss: Experience from the Middle East Gulf Region and Literature Review.
- New Drug: Tirzepatide (Mounjaro<sup>™</sup>).
- Semaglutide Plus Metformin Versus Metformin Alone For Antipsychotic-Induced Weight Gain In Patients With Type 2 Diabetes Mellitus.
- Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
- Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis.
- Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.
- Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus.